GlassScriptPhysician profile
John Fox
NPI 1982998399
$182,692.25
in general payments reported to CMS, 2019-2025
35 companies · $88K in 2025
The $88K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,770 · 2020: $5,542 · 2021: $1,425 · 2022: $13K · 2023: $13K · 2024: $52K · 2025: $88K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Consulting Fee: $25K · Travel and Lodging: $11K · Food and Beverage: $8,860 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,287.60 |
| Consulting Fee | $25,221.00 |
| Travel and Lodging | $11,171.76 |
| Food and Beverage | $8,859.87 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $78,499.17 | 2019-2025 | |
| Pfizer INC. | $49,025.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $44,959.26 | 2019-2025 | Dupixent |
| Abbvie INC. | $1,536.44 | 2019-2025 | |
| Janssen Biotech, INC. | $1,325.88 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $895.44 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $732.64 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $687.41 | 2020-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $650.49 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Incyte Corporation | $608.15 | 2021-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $587.26 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $569.18 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $444.89 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Ucb, INC. | $424.64 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $341.56 | 2021-2025 | Otezla, Otezla |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $291.07 | 2019-2022 | |
| Dermira, INC. | $241.38 | 2019-2020 | |
| Journey Medical Corporation | $92.51 | 2019-2025 | |
| Almirall LLC | $87.39 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $79.46 | 2025 | Acthar |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Dermavant Sciences, INC. | $69.79 | 2023-2024 | Vtama |
| Mission Pharmacal Company | $57.07 | 2019-2021 | |
| Organon LLC | $56.42 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $53.38 | 2023-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $52.65 | 2020-2021 | |
| Medimetriks Pharmaceuticals, INC. | $41.29 | 2020-2022 | |
| Prugen, INC. Pharmaceuticals | $40.68 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.86 | 2024 | Spevigo |
| Arcutis Biotherapeutics, INC. | $34.98 | 2023-2024 | Zoryve |
| Celgene Corporation | $24.12 | 2019 | |
| Stemline Therapeutics INC. | $21.09 | 2020 | |
| Paratek Pharmaceuticals, INC. | $19.73 | 2025 | Nuzyra |
| Verrica Pharmaceuticals INC. | $18.18 | 2024 | Ycanth |
| Merck Sharp & Dohme LLC | $14.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.